Home > Dermatology > SPIN 2022 > IMIDs in Adults and Children: New Developments > Therapies for atopic dermatitis: still moving forward

Therapies for atopic dermatitis: still moving forward

Presented By
Prof. Christian Vestergaard, Aarhus University Hospital, Denmark
Conference
SPIN 2022
Doi
https://doi.org/10.55788/25a7d0de
The armamentarium of topical and systemic treatments for atopic dermatitis (AD) is constantly growing. In the future, this will not only allow for higher therapeutic goals in the cutaneous domain but may also broaden the choice of targets in features like comorbidities. “Over the last couple of years, we have seen new treatments, and there are still new ones coming – is this really the revolution for AD?” Prof. Christian Vestergaard (Aarhus University Hospital, Denmark) asked, laying the land for his talk [1]. The incidence of AD has risen by 2–3 times over the last 3 decades, making it the most prevalent skin disease. Although the proportion of children with AD (15–20%) is higher than the percentage of adults (2–10%), numerically, adults are more common as patients. At the beginning of AD, genetic and environmental factors impair the skin barrier. As part of the type-2 inflammation cascade, the skin generates upstream molecules such as TARC, TSLP,...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on